Low-dose nivolumab for advanced cancer
Treatments studied
Part of Blood & lymphatic, Cancer, Digestive system, Immune system & allergy, Infections, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial tests a lower dose of nivolumab (an immunotherapy drug) given less frequently to treat cancers that have spread or cannot be surgically removed. The goal is to see if this approach works well while reducing side effects compared to standard dosing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have one of these cancer types that has spread or cannot be removed surgically: lung cancer, head/neck cancer, kidney cancer, melanoma, lymphoma, bladder cancer, cervical cancer, colorectal cancer, or Kaposi sarcoma
- Your cancer has progressed despite prior treatment or you are not a good candidate for standard curative therapies
- You have at least one measurable tumor visible on imaging
- You are 18 years or older with good overall health (ECOG score 0–2, meaning you can carry out most daily activities)
- Your blood counts and organ function are adequate for treatment
- You have never received immunotherapy drugs called checkpoint inhibitors before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a drug called Nivolumab (an immunotherapy) for people with rare solid tumors that have high levels of PD-L1. It might be an option if you have tried other treatments and they stopped working or caused too many side effects.
This Phase 1 trial tests a new combination of PBF-1129 with nivolumab (an immune therapy) for lung cancer that has come back or spread. It aims to find a safe dose and see whether the combination can shrink tumors and improve outcomes.
This study compares giving the immunotherapy drug nivolumab as a shot under the skin at home versus in the clinic. It is for people with certain cancers who are already taking or starting nivolumab.
This trial tests whether combining two immunotherapy medicines—cabozantinib and nivolumab—can shrink advanced melanoma or certain head-and-neck squamous cell cancers. It is mainly for people whose cancer has grown after prior PD-1 treatment.
This trial studies nivolumab, an immune therapy, for skin squamous cell cancer that can’t be cured with surgery or radiation. It aims to see how well the treatment shrinks tumors and helps people live longer or longer without cancer growth.
This trial tests whether adding the immunotherapy drug nivolumab to standard treatment works better for advanced stomach or esophageal cancer. It is for people whose cancer has already progressed after a first round of chemo plus immunotherapy.
Hear when a new Clinical Stage III Cutaneous Melanoma AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.